|
|
|
|
|
|
|
|
- [PDF]
- [JCO Podcast]
- Breast Cancer RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
- [Abstract]
- [JCO Podcast]
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.